Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

59.00USD
15 Dec 2017
Change (% chg)

$-1.15 (-1.91%)
Prev Close
$60.15
Open
$60.30
Day's High
$61.05
Day's Low
$58.90
Volume
229,702
Avg. Vol
169,800
52-wk High
$66.55
52-wk Low
$35.50

Latest Key Developments (Source: Significant Developments)

Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
Thursday, 16 Nov 2017 04:01pm EST 

Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - ‍for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018​.  Full Article

Aerie Pharmaceuticals Q3 loss per share $0.89
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - ‍as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments​.  Full Article

Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
Friday, 13 Oct 2017 07:05am EDT 

Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​.  Full Article

Aerie Pharmaceuticals announces drug delivery asset acquisition
Thursday, 5 Oct 2017 06:00am EDT 

Oct 5 (Reuters) - Aerie Pharmaceuticals Inc : :Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program.Aerie Pharmaceuticals Inc - has acquired from Envisia Therapeutics Inc rights to use print technology in ophthalmology and certain other assets.Aerie Pharmaceuticals Inc - ‍Envisia will receive an initial $25 million in form of a combination of cash and Aerie common stock​.Aerie Pharmaceuticals Inc - expect to initiate ‍clinical trials for AR-13154 within next 18 to 24 months​.Aerie Pharmaceuticals Inc - ‍in addition, Aerie acquired Envisia's intellectual property rights relating to ENV1105​.  Full Article

Aerie Pharmaceuticals comments on notification from contract manufacturer
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍received notification by its contract drug product manufacturer that contract manufacturer received CRL from U.S FDA.Aerie Pharmaceuticals - ‍CRL from FDA regarding contract manufacturer's NDA for one of their own product candidates manufactured at Tampa, Florida facility​.Aerie Pharmaceuticals Inc - ‍according to contract manufacturer, CRL refers to a Current Good Manufacturing Practice (CGMP) inspection at facility​.Aerie Pharmaceuticals Inc - ‍contract manufacturer has stated that they will work closely with FDA to determine appropriate next steps​.Aerie Pharmaceuticals Inc - ‍currently believe it is probable that open issues will be resolved prior to February 28, 2018 PDUFA date for Rhopressa​.  Full Article

Aerie Pharmaceuticals Q2 adj loss $0.63/shr
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 adjusted loss per share $0.63.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Q2 GAAP loss per share $0.82.  Full Article

Aerie Pharmaceuticals enters into collaboration agreement with DSM
Monday, 31 Jul 2017 06:30am EDT 

July 31 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD.Aerie Pharmaceuticals-terms of agreement with DSM were not disclosed and agreement is immaterial to Aerie based on level of current financial commitments.  Full Article

Aerie Pharmaceuticals reports positive Roclatan phase 3 12-month topline safety results
Wednesday, 19 Jul 2017 04:01pm EDT 

July 19 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 12-month topline safety results.Aerie Pharmaceuticals Inc - ‍roclatan successfully demonstrates a positive safety profile and efficacy levels consistent with previously reported results​.Says ‍continue to expect to submit our roclatan™ NDA (new drug application) in first half of 2018​.  Full Article

Brian Grossman reports 6.3 pct passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing
Monday, 17 Jul 2017 04:52pm EDT 

July 17 (Reuters) - Aerie Pharmaceuticals Inc :Brian Grossman reports 6.3 percent passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing.  Full Article

Aerie Pharmaceuticals raises $125 mln
Friday, 26 May 2017 06:30am EDT 

May 26 (Reuters) - Aerie Pharmaceuticals Inc ::Aerie Pharmaceuticals raises $125 million in ATM sales and upsized follow-on offering.Aerie Pharmaceuticals -priced registered underwritten public offering of $75 million of shares of its common stock at a price to public of $53.75 per share.Aerie Pharmaceuticals-to use proceeds to fund expansion of commercialization programs in north america for rhopressa, roclatan, among others.Aerie Pharmaceuticals- $125 million is in addition to $50 million of shares sold through completion with Cantor Fitzgerald & Co.  Full Article

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage: